Psychiatric aspects of irritable bowel syndrome.
The considerable psychiatric comorbidity in patients with irritable bowel syndrome (IBS) is noted and the concept of depressive spectrum disorder is briefly discussed. The results of a recently published study examining the effect of psychiatric comorbidity on the outcome of IBS are presented and discussed. Finally, details of a double-blind, placebo-controlled trial of Nefazodone in the treatment of patients with IBS, which has recently begun in South Wales, are discussed. (Int J Psych Clin Pract 1997; 1: 73-74).